Opko Health

Opko Health is selling its BioReference labs division to LabCorp for $722 million in cash plus $150 million in earn-outs, shifting its focus entirely to drug development.

The American biopharma company Opko Health stunned investors on the Tel Aviv Stock Exchange with stronger-than-expected quarterly results, a dramatic reduction in net loss, and an upward revision of its annual revenue forecast beyond market analyst estimates.